STOCK TITAN

AIM ImmunoTech Inc - AIM STOCK NEWS

Welcome to our dedicated news page for AIM ImmunoTech (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on AIM ImmunoTech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AIM ImmunoTech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AIM ImmunoTech's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial covid-19
-
Rhea-AI Summary
AIM ImmunoTech Inc. announced that its CEO and Scientific Officer will participate in the Virtual Investor Summer Spotlight Series on July 12th. The presentation will be available via live video webcast on the company's website, with a replay available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
conferences
-
Rhea-AI Summary
AIM ImmunoTech announces publication of pre-clinical data suggesting Ampligen's potential to reduce tumor cell growth in pancreatic cancer patients with sufficient tumor levels of TLR-3.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.66%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.66%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
clinical trial covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
AIM ImmunoTech Inc

NYSE:AIM

AIM Rankings

AIM Stock Data

24.71M
45.42M
8.99%
8.32%
0.99%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Ocala

About AIM

aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as